+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07303660

Evaluation of Lonitoclax Combined with Azacitidine for Relapsed or Refractory Acute Myeloid Leukemia Patients

Led by Lomond Therapeutics Holdings, Inc. · Updated on 2026-08-31

66

Participants Needed

6

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and early effects of the drug combination ZE50-0134 and Azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia AML. This open-label Phase 1b study focuses on patients who have not responded to previous treatments or whose disease has returned. The study aims to find the best dose and schedule of this combination therapy using a 3 3 dose escalation design before expanding to a larger group of patients. The study has two parts first, a dose escalation phase where different doses of Lonitoclax ZE50-0134 combined with Azacitidine are tested to find the biologically effective dose. Then, an expansion phase will enroll about 30 patients divided into two groups receiving different dose levels to determine the recommended phase 2 dose. Treatments include oral capsules of ZE50-0134 given once or twice daily and Azacitidine administered at 75 mgm2 daily for 7 days. Adjustments to doses may occur based on tolerability and safety findings. Participants will be involved in up to 24 cycles of treatment, each lasting 4 weeks. They will undergo assessments including safety monitoring and measuring responses to treatment. Researchers will evaluate how well patients blood counts recover, monitor side effects, and track event-free survival and remission duration. Close monitoring during treatment helps understand the best dosing and safety profile of the combination. The total study duration may extend up to nearly two years, including follow-up periods.

CONDITIONS

Brief Title

A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

Research Team

E

Ekaterina Dokukina

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here